All In MedTech

Device Trial Radar · NCT05730023

A Multimodal Approach for Clinical Diagnosis and Treatment of Primary Progressive Aphasia, MAINSTREAM ID:3430931

Last checked: Nov 20, 2026Latest source record: Nov 20, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

70

Actual

Start

Feb 1, 2023

Primary completion

Jan 13, 2026

Study completion Jan 13, 2026

Sponsor

Lead sponsor
IRCCS Centro San Giovanni di Dio FatebenefratelliAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Fondazione Regionale per la Ricerca Biomedica; IRCCS National Neurological Institute "C. Mondino" Foundation; Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico; Fondazione Don Carlo Gnocchi ETS
First posted
Feb 15, 2023

More device trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable (typical for device studies)
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, care provider, outcomes assessor)
Primary purpose
Treatment
FDA-regulated device
No
Who can join
All sexes, from 40 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Primary Progressive Aphasia (PPA) is a syndrome due to different neurodegenerative disorders selectively disrupting language functions. PPA specialist care is underdeveloped. There are very few specialists (neurologists, psychiatrists, neuropsychologists and speech therapists) and few hospitals- or community-based services dedicated to diagnosis and continuing care. Currently, healthcare systems struggle to provide adequate coverage of diagnostic services, and care is too often fragmented, uncoordinated, and unresponsive to the needs of people with PPA and their families. Recently attention has been gained by digital-health technologies, such immunoassay analyzer and high-field MRI, the most promising approaches to increase our understanding of neurodegeneration, and by new non-invasive brain stimulation techniques such as transcranial direct current stimulation (tDCS) that allow a personalized treatment approach. Our goal is to develop a new treatment approach in PPA in which the regional secondary care centers participating in this project should be the hub of a regional network. The MAINSTREAM (WP2- Efficacy of personalized training in the early stage of PPA) looks forward to introduce and evaluate therapeutic innovation such as tDCS coupled with language therapy in rehabilitation settings (WP2 Early Treatment). This objective will be pursued by conducting a randomized controlled pilot study in order to evaluate the efficacy of a combined treatment of Active (anodal) tDCS and individualized language training compared to Placebo tDCS combined with individualized language training in a subgroup of mild PPA defined using the Progressive Aphasia Severity Scale (PASS) (Sapolsky D, Domoto-Reilly K, Dickerson BCJA. Use of the Progressive Aphasia Severity Scale (PASS) in Monitoring Speech and Language Status in PPA. (2014) 28(8-9):993-1003).

Conditions

  • Primary Progressive Aphasia

Interventions

  • Active tDCSDevice

    Active tDCS (anode will be applied over the left DLPFC with the cathode over the right supraorbital region);

  • individualized language trainingBehavioral

    individualized language training

  • Placebo tDCSDevice

    Placebo tDCS (the current will be turned off 10 seconds after the beginning and turned on for the last 10 seconds of the stimulation period);

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change in measure of naming as assessed by International Picture Naming Project Task (IPNP)Time frame: Baseline up to 2 weeks and 3 months

Locations

4 sites in 1 country. Site status is shown where the registry gives one.

  • Francesca Baglio

    Milan, Italy

3 more study sites with a free account

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.